Thus, we evaluated the cost-effectiveness of osimertinib versus chemotherapy for previously-treated EGFR T790M positive NSCLC from the perspectives of the United States payer and Chinese healthcare system, based on updated data from the AURA3 trial. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.